Advanced Search

National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2012 (No. 1) (No. PB 21 of 2012)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
PB 21 of 2012
National Health (Botulinum Toxin Program) Special Arrangement Amendment Instrument 2012 (No. 1)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 26  March 2012
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1          Name of Instrument
            (1)        This Instrument is the National Health (Botulinum Toxin Program)
                        Special Arrangement Amendment Instrument 2012 (No.1).
            (2)        This Instrument may also be cited as PB 21 of 2012.
2          Commencement
(1)       This instrument commences on 1 April 2012.
3          Amendment of PB 89 of 2011
            Schedule 1 amends the National Health (Botulinum Toxin Program) Special Arrangement 2011 (PB 89 of 2011).
4          Transitional
            A medical practitioner authorised under subsection 18(1) of PB 89 of 2011 immediately prior to the commencement of this instrument to administer botulinum toxin pharmaceutical benefits for the treatment condition ‘Treatment of blepharospasm or hemifacial spasm’ is, after the commencement of this Instrument, taken to be authorised to administer botulinum toxin pharmaceutical benefits for the treatment conditions ‘Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older’ and ‘Treatment of blepharospasm or hemifacial spasm in an adult’.
 
 
 
 
 
Schedule 1     Amendments
[1]        Subsection 18(4), after spasm (first occurring)
insert:
in a patient 12 years or older and/or the treatment of blepharospasm or hemifacial spasm in an adult
[2]        Subparagraph 18(4)(b)(ii)
omit:
condition blepharospasm or hemofacial spasm
substitute:
conditions numbered 1 and/or 1A
[3]        Subsection 18(5), after spasm (first occurring)
insert:
in a patient 12 years or older and/or the treatment of blepharospasm or hemifacial spasm in an adult
[4]         Subparagraph 18(5)(b)(ii)
omit:
condition blepharospasm or hemofacial spasm
substitute:
conditions numbered 1 and/or 1A
[5]         Schedule 1, after
 
Botulinum Toxin Type A Purified Neurotoxin Complex
Lyophilised powder for injection 100 units
Injection
Botox
AG
D
insert:
Clostridium Botulinum Type A Toxin-Haemagglutinin Complex
Lyophilised powder for injection 300 units
Injection
Dysport
IS
D
[6]        Schedule 3
omit:
1
Treatment of blepharospasm or hemifacial spasm
Botulinum Toxin Type A Purified Neurotoxin Complex
Neurology
Opthalmology
Otolaryngology head and neck surgery
Plastic Surgery
substitute:
1
Treatment of blepharospasm or hemifacial spasm in a patient 12 years or older
Botulinum Toxin Type A Purified Neurotoxin Complex
Neurology
Opthalmology
Otolaryngology head and neck surgery
Plastic Surgery

1A
Treatment of blepharospasm or hemifacial spasm in an adult
Clostridium Botulinum Type A Toxin-Haemagglutinin Complex
Neurology
Opthalmology
Otolaryngology head and neck surgery
Plastic Surgery

 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the
Legislative Instruments Act 2003.  See http://www.frli.gov.au.